Abstracts tagged "sarcoidosis and tumor necrosis factor (TNF)"

Abstract Number: 2127 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors for Sarcoidosis
Stefanie Wade¹ and Mollie Carruthers², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with sarcoidosis refractory to standard treatment are a therapeutic challenge and are often managed by a variety of specialists due to the heterogeneity…
Abstract Number: 1397 • 2015 ACR/ARHP Annual Meeting
Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy
Maya Estephan¹, Mehrdad Maz², Mark Hamblin³ and Julian Magadan¹, ¹Division of Allergy, Clinical Immunology, and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³Pulmonary and Critical Care Medicine, ILD Clinic, University of Kansas Medical Center, Kansas city, KS
Background/Purpose: Although cardiac involvement is symptomatic in only 5% of patients with sarcoidosis, it is considered an important prognostic factor and the second leading cause…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.